698396-39-3

Upstream product

• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 304465-35-8 1-(4-nitrophenyl)-2-oxo-2,5-dihydro-1H-pyrido[3,2-b]indole-3-carbonitrile 
• 105-56-6 ethyl 2-cyanoacetate 
• 167954-14-5 3-[N-(4-nitrophenyl)amino]-2-formylindole 
• 167954-19-0 3-[N-(4-nitrophenyl)amino]indole 
• 100-01-6 4-nitro-aniline 
• 67766-00-1 N-acetyl-3-p-nitrophenylaminoindole 
• 33025-60-4 1-(3-hydroxy-1H-indol-1-yl)ethanone 

Relevant academic research and scientific papers

PROCESS FOR PREPARING 2-OXO-2,5-DIHYDRO-1H-PYRIDO[3,2-B]INDOLE-3-CARBONITRILES

A process for preparing 2-oxo-2,5-dihydro-1H-pyrido[3,2-b]indole-3-carbonitriles starting from 1-substituted indole-2-carboxaldehyde with an aromatic amine and reacting the thus obtained intermediate with a cyanoacetic acid ester.

COMBINATIONS OF SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO- [3,2-B] INDOL-2-ONES AND OTHER HIV INHIBITORS

The present invention concerns combinations comprising a compound of formula (I); the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters or metabolites thereof, wherein n is 1, 2 or 3; R1 is H, CN, halo, aminoC(=O), C(=O)OH, C1-4alkyloxyC(=O), C1-4 alkylC(=O), mono- or di(C1-4alkyl)aminoC(=O), arylaminoC(=O), N-(aryl)-N-(C1-4 alkyl)aminoC(=O), methanimidamidyl,N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; R2 is H, C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl, C2-10alkenyl and C3-7 cycloalkyl may be optionally substituted; R3 is nitro, cyano, amino, halo, hydroxy, C1-4alkyloxy, hydroxyC(=O), aminoC(=O), C1-4alkyloxyC(=O), mono- or di(C1-4alkyl)aminoC(=O), C1-4alkylC(=O), methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl,N-hydroxy-methanimidamidyl or Het1; and another HIV inhibitor. The invention also concerns products comprising a compound of formula (I) and another HIV inhibitor, as a combined preparation for simultaneous, separate or sequential use in treatment of retroviral infections such as HIV infection, in particular, in the treatment of infections with multi-drug resistant retroviruses.